DNMT3A and neoplasm: In solid tumor (including glioma) CAR-T models, DNMT3A deficiency boosted CAR-T expansion, cytokine secretion, and lysis; after chronic stimulation, these cells showed higher TCF1/LEF1 and stem/naive-like epigenetics, increasing in vivo anti-tumor activity (123, 124).